Appendix D: Acronyms
Updated
Reviewed
Oct. 26, 2016
| Acronym/Abbreviation | Full Name |
|---|---|
| 3TC | lamivudine |
| ABC | abacavir |
| ACOG | American College of Obstetricians and Gynecologists |
| ALT | alanine aminotransferase |
| anti-HBc | anti-hepatitis B core antibody |
| anti-HBS | hepatitis B surface antibody |
| AOR | adjusted odds ratio |
| AP | antepartum |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AST | aspartate aminotransferase |
| ATV | atazanavir |
| ATV/r | atazanavir/ritonavir |
| AUC | area under the curve |
| AZT | zidovudine |
| BID | twice daily |
| BMI | body mass index |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CNS | central nervous system |
| COBI | cobicistat |
| CVS | chorionic villus sampling |
| CYP | cytochrome P |
| CYP3A4 | cytochrome P450 3A4 |
| d4T | stavudine |
| ddI | didanosine |
| DMPA | depot medroxyprogesterone acetate |
| DRV | darunavir |
| DRV/r | darunavir/ritonavir |
| DSMB | Data and Safety Monitoring Board |
| DTG | dolutegravir |
| EC | enteric coated |
| ECG | electrocardiogram |
| EFV | efavirenz |
| EMS | ethyl methane sulfonate |
| ETR | etravirine |
| EVG | elvitegravir |
| FDA | Food and Drug Administration |
| FDC | fixed drug combination |
| FPV | fosamprenavir |
| FPV/r | fosamprenavir/ritonavir |
| FTC | emtricitabine |
| gp | glycoprotein |
| HAV | hepatitis A virus |
| HBIG | hepatitis B immune globulin |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HELLP | hemolysis, elevated liver enzymes, and low platelets |
| HGC | hard gel capsule |
| HR | hazard ratio |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| IC50 | inhibitory concentration 50% |
| IDV | indinavir |
| IDV/r | indinavir/ritonavir |
| IGF | insulin-like growth factor |
| IgG | Immunoglobulin G |
| IP | intrapartum |
| IQR | interquartile range |
| IRIS | immune reconstitution inflammatory syndrome |
| IUD | intrauterine device |
| IV | intravenous/intravenously |
| LPV | lopinavir |
| LPV/r | lopinavir/ritonavir |
| MAC | Mycobacterium avium complex |
| mtDNA | mitochondrial DNA |
| MVC | maraviroc |
| NFV | nelfinavir |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor |
| NtRTI | nucleotide analogue reverse transcriptase inhibitor |
| NVP | nevirapine |
| OC | oral contraceptive |
| OI | opportunistic infection |
| OR | odds ratio |
| The Panel | The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PP | postpartum |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| PTD | preterm delivery |
| RAL | raltegravir |
| RDS | respiratory distress syndrome |
| RPV | rilpivirine |
| RR | relative risk |
| RTV | ritonavir |
| SD | single dose |
| SQ | subcutaneous |
| SQV | saquinavir |
| SQV/r | saquinavir/ritonavir |
| STD | sexually transmitted disease |
| T20 | enfuvirtide |
| TAF | tenofovir alafenamide |
| TDF | tenofovir disoproxil fumarate |
| TDM | therapeutic drug monitoring |
| TID | three times daily |
| TPV | tipranavir |
| TPV/r | tipranavir/ritonavir |
| UGT | uridine diphosphate glucuronosyltransferase |
| WHO | World Health Organization |
| ZDV | zidovudine |
| Acronym/Abbreviation | Full Name |
|---|---|
| 3TC | lamivudine |
| ABC | abacavir |
| ACOG | American College of Obstetricians and Gynecologists |
| ALT | alanine aminotransferase |
| anti-HBc | anti-hepatitis B core antibody |
| anti-HBS | hepatitis B surface antibody |
| AOR | adjusted odds ratio |
| AP | antepartum |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AST | aspartate aminotransferase |
| ATV | atazanavir |
| ATV/r | atazanavir/ritonavir |
| AUC | area under the curve |
| AZT | zidovudine |
| BID | twice daily |
| BMI | body mass index |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CNS | central nervous system |
| COBI | cobicistat |
| CVS | chorionic villus sampling |
| CYP | cytochrome P |
| CYP3A4 | cytochrome P450 3A4 |
| d4T | stavudine |
| ddI | didanosine |
| DMPA | depot medroxyprogesterone acetate |
| DRV | darunavir |
| DRV/r | darunavir/ritonavir |
| DSMB | Data and Safety Monitoring Board |
| DTG | dolutegravir |
| EC | enteric coated |
| ECG | electrocardiogram |
| EFV | efavirenz |
| EMS | ethyl methane sulfonate |
| ETR | etravirine |
| EVG | elvitegravir |
| FDA | Food and Drug Administration |
| FDC | fixed drug combination |
| FPV | fosamprenavir |
| FPV/r | fosamprenavir/ritonavir |
| FTC | emtricitabine |
| gp | glycoprotein |
| HAV | hepatitis A virus |
| HBIG | hepatitis B immune globulin |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HELLP | hemolysis, elevated liver enzymes, and low platelets |
| HGC | hard gel capsule |
| HR | hazard ratio |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| IC50 | inhibitory concentration 50% |
| IDV | indinavir |
| IDV/r | indinavir/ritonavir |
| IGF | insulin-like growth factor |
| IgG | Immunoglobulin G |
| IP | intrapartum |
| IQR | interquartile range |
| IRIS | immune reconstitution inflammatory syndrome |
| IUD | intrauterine device |
| IV | intravenous/intravenously |
| LPV | lopinavir |
| LPV/r | lopinavir/ritonavir |
| MAC | Mycobacterium avium complex |
| mtDNA | mitochondrial DNA |
| MVC | maraviroc |
| NFV | nelfinavir |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor |
| NtRTI | nucleotide analogue reverse transcriptase inhibitor |
| NVP | nevirapine |
| OC | oral contraceptive |
| OI | opportunistic infection |
| OR | odds ratio |
| The Panel | The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PP | postpartum |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| PTD | preterm delivery |
| RAL | raltegravir |
| RDS | respiratory distress syndrome |
| RPV | rilpivirine |
| RR | relative risk |
| RTV | ritonavir |
| SD | single dose |
| SQ | subcutaneous |
| SQV | saquinavir |
| SQV/r | saquinavir/ritonavir |
| STD | sexually transmitted disease |
| T20 | enfuvirtide |
| TAF | tenofovir alafenamide |
| TDF | tenofovir disoproxil fumarate |
| TDM | therapeutic drug monitoring |
| TID | three times daily |
| TPV | tipranavir |
| TPV/r | tipranavir/ritonavir |
| UGT | uridine diphosphate glucuronosyltransferase |
| WHO | World Health Organization |
| ZDV | zidovudine |
Download Guidelines
- Section OnlyPDF (745.26 KB)
- Full GuidelinePDF (4.91 MB)
- Recommendations OnlyPDF (313.35 KB)
- Tables OnlyPDF (572.94 KB)